Last reviewed · How we verify

Teneli (Teneligliptin) — Competitive Intelligence Brief

Teneli (Teneligliptin) (Teneli (Teneligliptin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

marketed DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Teneli (Teneligliptin) (Teneli (Teneligliptin)) — Tanabe Pharma Corporation. Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Teneli (Teneligliptin) TARGET Teneli (Teneligliptin) Tanabe Pharma Corporation marketed DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4)
sitagliptin and acarbose sitagliptin and acarbose Nanjing First Hospital, Nanjing Medical University marketed DPP-4 inhibitor + alpha-glucosidase inhibitor combination DPP-4 enzyme; alpha-glucosidase enzymes
DPP-4 inhibitor + metformin group DPP-4 inhibitor + metformin group Beni-Suef University marketed DPP-4 inhibitor + biguanide combination DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
Galvus (vildagliptin) Galvus (vildagliptin) Korea University Anam Hospital marketed DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4)
alogliptin + pioglitazone alogliptin + pioglitazone Kun-Ho Yoon marketed DPP-4 inhibitor + thiazolidinedione DPP-4 and PPAR-γ
Metformin and Saxagliptin Metformin and Saxagliptin ikfe-CRO GmbH marketed Biguanide + DPP-4 inhibitor combination Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)
Incretin-based therapy Incretin-based therapy Nagaoka Red Cross Hospital marketed Incretin mimetic or DPP-4 inhibitor GLP-1 receptor or DPP-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

  1. Merck Sharp & Dohme LLC · 5 drugs in this class
  2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. LG Life Sciences · 2 drugs in this class
  5. Tanabe Pharma Corporation · 2 drugs in this class
  6. Ain Shams University · 2 drugs in this class
  7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
  8. Cinnagen · 1 drug in this class
  9. GRADE Study Group · 1 drug in this class
  10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teneli (Teneligliptin) — Competitive Intelligence Brief. https://druglandscape.com/ci/teneli-teneligliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: